1. Home
  2. CELC vs MBAV Comparison

CELC vs MBAV Comparison

Compare CELC & MBAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • MBAV
  • Stock Information
  • Founded
  • CELC 2011
  • MBAV 2024
  • Country
  • CELC United States
  • MBAV United States
  • Employees
  • CELC N/A
  • MBAV N/A
  • Industry
  • CELC Medical Specialities
  • MBAV
  • Sector
  • CELC Health Care
  • MBAV
  • Exchange
  • CELC Nasdaq
  • MBAV NYSE
  • Market Cap
  • CELC 440.0M
  • MBAV 413.3M
  • IPO Year
  • CELC 2017
  • MBAV 2024
  • Fundamental
  • Price
  • CELC $13.04
  • MBAV $11.50
  • Analyst Decision
  • CELC Strong Buy
  • MBAV
  • Analyst Count
  • CELC 6
  • MBAV 0
  • Target Price
  • CELC $30.67
  • MBAV N/A
  • AVG Volume (30 Days)
  • CELC 196.9K
  • MBAV 515.0K
  • Earning Date
  • CELC 08-13-2025
  • MBAV 01-01-0001
  • Dividend Yield
  • CELC N/A
  • MBAV N/A
  • EPS Growth
  • CELC N/A
  • MBAV N/A
  • EPS
  • CELC N/A
  • MBAV 0.28
  • Revenue
  • CELC N/A
  • MBAV N/A
  • Revenue This Year
  • CELC N/A
  • MBAV N/A
  • Revenue Next Year
  • CELC N/A
  • MBAV N/A
  • P/E Ratio
  • CELC N/A
  • MBAV $41.31
  • Revenue Growth
  • CELC N/A
  • MBAV N/A
  • 52 Week Low
  • CELC $7.58
  • MBAV $9.97
  • 52 Week High
  • CELC $19.77
  • MBAV $13.73
  • Technical
  • Relative Strength Index (RSI)
  • CELC 60.10
  • MBAV N/A
  • Support Level
  • CELC $12.48
  • MBAV N/A
  • Resistance Level
  • CELC $13.60
  • MBAV N/A
  • Average True Range (ATR)
  • CELC 0.74
  • MBAV 0.00
  • MACD
  • CELC 0.04
  • MBAV 0.00
  • Stochastic Oscillator
  • CELC 75.91
  • MBAV 0.00

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About MBAV M3-BRIGADE ACQUISITION V CORP

M3-Brigade Acquisition V Corp is a blank check company.

Share on Social Networks: